Therapeutic targeting and patient selection for cancers with homologous recombination defects

References

• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009 Oct 22;461(7267):1071–1078.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007 May 25;316(5828):1160–1166.
   PubMed Web of Science ®Google Scholar
• Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell. 2002 Apr;109(Suppl):S45–55.
   PubMed Web of Science ®Google Scholar
• Fugmann SD, Lee AI, Shockett PE, et al. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol. 2000;18:495–527.
   PubMed Web of Science ®Google Scholar
• Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014 Jan;16(1):2–9.
   PubMed Web of Science ®Google Scholar
• Aymard F, Bugler B, Schmidt CK, et al. Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. Nat Struct Mol Biol. 2014 Apr;21(4):366–374.
   PubMed Web of Science ®Google Scholar
• Lieber MR. The mechanism of human nonhomologous DNA end joining. J Biol Chem. 2008 Jan 4;283(1):1–5.
   PubMed Web of Science ®Google Scholar
• Pitcher RS, Wilson TE, Doherty AJ. New insights into NHEJ repair processes in prokaryotes. Cell Cycle. 2005 May;4(5):675–678.
   PubMed Web of Science ®Google Scholar
• Ma Y, Lu H, Schwarz K, et al. Repair of double-strand DNA breaks by the human nonhomologous DNA end joining pathway: the iterative processing model. Cell Cycle. 2005 Sep;4(9):1193–1200.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan SK, Jette N, Lees-Miller SP. Non-homologous end joining: emerging themes and unanswered questions. DNA Repair (Amst). 2014 May;17:2–8.
   PubMed Web of Science ®Google Scholar
• Bennardo N, Cheng A, Huang N, et al. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. Plos Genet. 2008 Jun 27;4(6):e1000110.
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010 Mar;11(3):196–207.
   PubMed Web of Science ®Google Scholar
• Wyman C, Kanaar R. DNA double-strand break repair: all’s well that ends well. Annu Rev Genet. 2006;40:363–383.
   PubMed Web of Science ®Google Scholar
• Johnson RD, Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. Embo J. 2000 Jul 3;19(13):3398–3407.
   PubMed Web of Science ®Google Scholar
• Wu X, Ranganathan V, Weisman DS, et al. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature. 2000 May 25;405(6785):477–482.
   PubMed Web of Science ®Google Scholar
• Zhao S, Weng YC, Yuan SS, et al. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature. 2000 May 25;405(6785):473–477.
   PubMed Web of Science ®Google Scholar
• Anand R, Ranjha L, Cannavo E, et al. Phosphorylated CtIP functions as a co-factor of the MRE11-RAD50-NBS1 endonuclease in DNA end resection. Mol Cell. 2016 Dec 1;64(5):940–950.
   PubMed Web of Science ®Google Scholar
• Garcia V, Phelps SE, Gray S, et al. Bidirectional resection of DNA double-strand breaks by Mre11 and Exo1. Nature. 2011 Oct 16;479(7372):241–244.
   PubMed Web of Science ®Google Scholar
• Nimonkar AV, Genschel J, Kinoshita E, et al. BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev. 2011 Feb 15;25(4):350–362.
   PubMed Web of Science ®Google Scholar
• Sturzenegger A, Burdova K, Kanagaraj R, et al. DNA2 cooperates with the WRN and BLM RecQ helicases to mediate long-range DNA end resection in human cells. J Biol Chem. 2014 Sep 26;289(39):27314–27326.
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006 Sep 25;25(43):5864–5874.
   PubMed Web of Science ®Google Scholar
• Suwaki N, Klare K, Tarsounas M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin Cell Dev Biol. 2011 Oct;22(8):898–905.
   PubMed Web of Science ®Google Scholar
• Lok BH, Carley AC, Tchang B, et al. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene. 2013 Jul 25;32(30):3552–3558.
   PubMed Web of Science ®Google Scholar
• Badie S, Liao C, Thanasoula M, et al. RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation. J Cell Biol. 2009 May 18;185(4):587–600.
   PubMed Web of Science ®Google Scholar
• Swagemakers SM, Essers J, De Wit J, et al. The human RAD54 recombinational DNA repair protein is a double-stranded DNA-dependent ATPase. J Biol Chem. 1998 Oct 23;273(43):28292–28297.
   PubMed Web of Science ®Google Scholar
• Bugreev DV, Mazina OM, Mazin AV. Rad54 protein promotes branch migration of Holliday junctions. Nature. 2006 Aug 3;442(7102):590–593.
   PubMed Web of Science ®Google Scholar
• Moudry P, Watanabe K, Wolanin KM, et al. TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity. J Cell Biol. 2016 Feb 1;212(3):281–288.
   PubMed Web of Science ®Google Scholar
• Pace P, Mosedale G, Hodskinson MR, et al. Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science. 2010 Jul 9; 329(5988):219–223.
   PubMed Web of Science ®Google Scholar
• Ceccaldi R, Liu JC, Amunugama R, et al. Homologous-recombination-deficient tumours are dependent on poltheta-mediated repair. Nature. 2015 Feb 12;518(7538):258–262.
   PubMed Web of Science ®Google Scholar
• Kent T, Chandramouly G, McDevitt SM, et al. Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase theta. Nat Struct Mol Biol. 2015 Mar;22(3):230–237.
   PubMed Web of Science ®Google Scholar
• Sartori AA, Lukas C, Coates J, et al. Human CtIP promotes DNA end resection. Nature. 2007 Nov 22;450(7169):509–514.
   PubMed Web of Science ®Google Scholar
• Yu X, Chen J. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol. 2004 Nov;24(21):9478–9486.
   PubMed Web of Science ®Google Scholar
• Escribano-Diaz C, Orthwein A, Fradet-Turcotte A, et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell. 2013 Mar 7;49(5):872–883.
   PubMed Web of Science ®Google Scholar
• Isono M, Niimi A, Oike T, et al. BRCA1 directs the repair pathway to homologous recombination by promoting 53BP1 dephosphorylation. Cell Rep. 2017 Jan 10;18(2):520–532.
   PubMed Web of Science ®Google Scholar
• Boersma V, Moatti N, Segura-Bayona S, et al. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5ʹ end resection. Nature. 2015 May 28;521(7553):537–540.
   PubMed Web of Science ®Google Scholar
• Xu G, Chapman JR, Brandsma I, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015 May 28;521(7553):541–544.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Watanabe K, Akimov V, et al. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol. 2013 Dec;20(12):1425–1433.
   PubMed Web of Science ®Google Scholar
• Tkac J, Xu G, Adhikary H, et al. HELB is a feedback inhibitor of DNA end resection. Mol Cell. 2016 Feb 4;61(3):405–418.
   PubMed Web of Science ®Google Scholar
• Chroma K, Mistrik M, Moudry P, et al. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. Oncogene. 2016 Nov 14.
   PubMedGoogle Scholar
• Densham RM, Garvin AJ, Stone HR, et al. Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection. Nat Struct Mol Biol. 2016 Jul;23(7):647–655.
   PubMed Web of Science ®Google Scholar
• Yata K, Lloyd J, Maslen S, et al. Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. Mol Cell. 2012 Feb 10;45(3):371–383.
   PubMed Web of Science ®Google Scholar
• Schlacher K, Christ N, Siaud N, et al. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell. 2011 May 13; 145(4):529–542.
   PubMed Web of Science ®Google Scholar
• Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell. 2012 Jul 10;22(1):106–116.
   PubMed Web of Science ®Google Scholar
• Somyajit K, Saxena S, Babu S, et al. Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart. Nucleic Acids Res. 2015 Nov 16;43(20):9835–9855.
   PubMed Web of Science ®Google Scholar
• Strom CE, Johansson F, Uhlen M, et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011 Apr;39(8):3166–3175.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012 Nov 1;72(21):5588–5599.
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri A, Callen E, Ding X, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016 Jul 20;535(7612):382–387.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994 Oct 7;266(5182):120–122.
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71.
   PubMed Web of Science ®Google Scholar
• Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996 Mar;12(3):333–337.
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21-28;378(6559):789–792.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012 Dec 4;107(12):2005–2009.
   PubMed Web of Science ®Google Scholar
• Thompson D, Easton DF. Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002 Sep 18;94(18):1358–1365.
   PubMed Web of Science ®Google Scholar
• Mersch J, Jackson M, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015 Jul 15;121(14):2474–2475.
   PubMed Web of Science ®Google Scholar
• Osorio A, De La Hoya M, Rodriguez-Lopez R, et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer. 2002 May 10;99(2):305–309.
   PubMed Web of Science ®Google Scholar
• Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000 Apr 5;92(7):564–569.
   PubMedGoogle Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Moschetta M, George A, Kaye SB, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016 Aug;27(8):1449–1455.
   PubMed Web of Science ®Google Scholar
• Ramus SJ, Song H, Dicks E, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst. 2015 Aug 27;107(11). Print 2015 Nov. doi:10.1093/jnci/djv214.
   PubMedGoogle Scholar
• Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014 Aug 7;371(6):497–506.
   PubMed Web of Science ®Google Scholar
• Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015 Sep 10;33(26):2901–2907.
   PubMed Web of Science ®Google Scholar
• Minion LE, Dolinsky JS, Chase DM, et al. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol Oncol. 2015 Apr;137(1):86–92.
   PubMed Web of Science ®Google Scholar
• Frimer M, Levano KS, Rodriguez-Gabin A, et al. Germline mutations of the DNA repair pathways in uterine serous carcinoma. Gynecol Oncol. 2016 Apr;141(1):101–107.
   PubMed Web of Science ®Google Scholar
• Chae YK, Anker JF, Carneiro BA, et al. Genomic landscape of DNA repair genes in cancer. Oncotarget. 2016 Apr 26;7(17):23312–23321.
   PubMed Web of Science ®Google Scholar
• Meijers-Heijboer H, Van Den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002 May;31(1):55–59.
   PubMed Web of Science ®Google Scholar
• Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002 Aug;71(2):432–438.
   PubMed Web of Science ®Google Scholar
• Lee JS, Collins KM, Brown AL, et al. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature. 2000 Mar 9;404(6774):201–204.
   PubMed Web of Science ®Google Scholar
• Zhang J, Willers H, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol. 2004 Jan;24(2):708–718.
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May;72(5):1117–1130.
   PubMed Web of Science ®Google Scholar
• Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271.
   PubMed Web of Science ®Google Scholar
• Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013 Jun 5;105(11):812–822.
   PubMedGoogle Scholar
• Shive HR, West RR, Embree LJ, et al. BRCA2 and TP53 collaborate in tumorigenesis in zebrafish. Plos One. 2014 Jan 29;9(1):e87177.
   PubMed Web of Science ®Google Scholar
• van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011 Apr;34(2):71–88.
   PubMed Web of Science ®Google Scholar
• Jazaeri AA, Yee CJ, Sotiriou C, et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002 Jul 3;94(13):990–1000.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002 May 1;20(9):2310–2318.
   PubMed Web of Science ®Google Scholar
• Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 2000 Apr;66(4):1259–1272.
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008 Mar;8(3):193–204.
   PubMed Web of Science ®Google Scholar
• Gowen LC, Johnson BL, Latour AM, et al. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet. 1996 Feb;12(2):191–194.
   PubMed Web of Science ®Google Scholar
• Hakem R, De La Pompa JL, Sirard C, et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell. 1996 Jun 28;85(7):1009–1023.
   PubMed Web of Science ®Google Scholar
• Suzuki A, De La Pompa JL, Hakem R, et al. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. 1997 May 15;11(10):1242–1252.
   PubMed Web of Science ®Google Scholar
• Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997 Apr 24;386(6627):804–810.
   PubMed Web of Science ®Google Scholar
• Ludwig T, Chapman DL, Papaioannou VE, et al. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 1997 May 15;11(10):1226–1241.
   PubMed Web of Science ®Google Scholar
• Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell. 1998 Feb;1(3):347–357.
   PubMed Web of Science ®Google Scholar
• Elledge SJ, Amon A. The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. Cancer Cell. 2002 Mar;1(2):129–132.
   PubMed Web of Science ®Google Scholar
• Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000 Mar 10;287(5459):1824–1827.
   PubMed Web of Science ®Google Scholar
• Brodie SG, Xu X, Qiao W, et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene. 2001 Nov 8;20(51):7514–7523.
   PubMed Web of Science ®Google Scholar
• Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111–12116.
   PubMed Web of Science ®Google Scholar
• Crook T, Brooks LA, Crossland S, et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene. 1998 Oct 1;17(13):1681–1689.
   PubMed Web of Science ®Google Scholar
• Evers B, Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene. 2006 Sep 25;25(43):5885–5897.
   PubMed Web of Science ®Google Scholar
• Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 2011 Jun 24;11(7):467–480.
   PubMed Web of Science ®Google Scholar
• Kee Y, D’Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010 Aug 15;24(16):1680–1694.
   PubMed Web of Science ®Google Scholar
• Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002 Jul 26;297(5581):606–609.
   PubMed Web of Science ®Google Scholar
• Sawyer SL, Tian L, Kahkonen M, et al.; University of Washington Centre for Mendelian Genomics. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 2015 Feb;5(2):135–142.
   PubMed Web of Science ®Google Scholar
• Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross)linked to DNA repair. Cell. 2005 Dec 29;123(7):1191–1198.
   PubMed Web of Science ®Google Scholar
• Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012 Jul 20;30(21):2654–2663.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010 Aug 1;28(22):3570–3576.
   PubMed Web of Science ®Google Scholar
• Lesnock JL, Darcy KM, Tian C, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study. Br J Cancer. 2013 Apr 2;108(6):1231–1237.
   PubMed Web of Science ®Google Scholar
• Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008 Dec 1;26(34):5530–5536.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Nygren AO, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12117–12122.
   PubMed Web of Science ®Google Scholar
• Sharma P, Lopez-Tarruella S, Garcia-Saenz JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. Clin Cancer Res. 2017 Feb 1;23(3):649–657.
   PubMed Web of Science ®Google Scholar
• Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1145–1153.
   PubMed Web of Science ®Google Scholar
• Vollebergh MA, Lips EH, Nederlof PM, et al. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 2014 May 15;16(3):R47.
   PubMed Web of Science ®Google Scholar
• Lucchesi JC. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics. 1968 May;59(1):37–44.
   PubMed Web of Science ®Google Scholar
• Hartwell LH, Szankasi P, Roberts CJ, et al. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997 Nov 7;278(5340):1064–1068.
   PubMed Web of Science ®Google Scholar
• Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 2008 Jan;18(1):27–47.
   PubMed Web of Science ®Google Scholar
• Purnell MR, Whish WJ. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J. 1980 Mar 1;185(3):775–777.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr 14;434(7035):917–921.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005 Apr 14;434(7035):913–917.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011 Sep;12(9):852–861.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123–134.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017 Mar 17;355(6330):1152–1158.
   PubMed Web of Science ®Google Scholar
• Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. Br J Cancer. 2016 Mar 29;114(7):713–715.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014 Feb;13(2):433–443.
   PubMed Web of Science ®Google Scholar
• Pommier Y, O’Connor MJ, De Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016 Oct 26;8(362):362ps17.
   PubMed Web of Science ®Google Scholar
• Shen Y, Rehman FL, Feng Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013 Sep 15;19(18):5003–5015.
   PubMed Web of Science ®Google Scholar
• Wang M, Wu W, Wu W, et al. PARP-1 and ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34(21):6170–6182.
   PubMed Web of Science ®Google Scholar
• Li B, Navarro S, Kasahara N, et al. Identification and biochemical characterization of a Werner’s syndrome protein complex with Ku70/80 and poly(ADP-ribose) polymerase-1. J Biol Chem. 2004 Apr 2;279(14):13659–13667.
   PubMed Web of Science ®Google Scholar
• Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011 Feb 22; 108(8):3406–3411.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244–250.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382–1392.
   PubMed Web of Science ®Google Scholar
• Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87–97.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852–861.
   PubMed Web of Science ®Google Scholar
• Van Der Noll R, Marchetti S, Steeghs N, et al. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. Br J Cancer. 2015 Jul 28;113(3):396–402.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016 Feb;140(2):199–203.
   PubMed Web of Science ®Google Scholar
• Lee JM, Hays JL, Annunziata CM, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014 May 19;106(6):dju089.
   PubMedGoogle Scholar
• Bindra RS, Schaffer PJ, Meng A, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol. 2004 Oct;24(19):8504–8518.
   PubMed Web of Science ®Google Scholar
• Lim JJ, Yang K, Taylor-Harding B, et al. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia. 2014 Apr;16(4):343,53.e1-2.
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006 Aug;7(8):606–619.
   PubMed Web of Science ®Google Scholar
• Kumar A, Fernandez-Capetillo O, Carrera AC. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7491–7496.
   PubMed Web of Science ®Google Scholar
• Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012 Nov;2(11):1048–1063.
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012 Nov;2(11):1036–1047.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Billalabeitia E, Seitzer N, Song SJ, et al. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014 Aug;4(8):896–904.
   PubMed Web of Science ®Google Scholar
• Johnson N, Li YC, Walton ZE, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med. 2011 Jun 26;17(7):875–882.
   PubMed Web of Science ®Google Scholar
• Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 2016 Nov 22;17(9):2367–2381.
   PubMed Web of Science ®Google Scholar
• Jirawatnotai S, Hu Y, Michowski W, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011 Jun 8;474(7350):230–234.
   PubMed Web of Science ®Google Scholar
• Bergs JW, Krawczyk PM, Borovski T, et al. Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining. DNA Repair (Amst). 2013 Jan 1;12(1):38–45.
   PubMed Web of Science ®Google Scholar
• Krawczyk PM, Eppink B, Essers J, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9851–9856.
   PubMed Web of Science ®Google Scholar
• Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008 Feb 28;451(7182):1116–1120.
   PubMed Web of Science ®Google Scholar
• Swisher EM, Sakai W, Karlan BY, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008 Apr 15; 68(8):2581–2586.
   PubMed Web of Science ®Google Scholar
• Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007 Nov;81(5):873–883.
   PubMed Web of Science ®Google Scholar
• Ter Brugge P, Kristel P, Van Der Burg E, et al. Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J Natl Cancer Inst. 2016 Jul 5;108(11). Print 2016 Nov. doi:10.1093/jnci/djw148.
   PubMedGoogle Scholar
• Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28;521(7553):489–494.
   PubMed Web of Science ®Google Scholar
• Cao L, Xu X, Bunting SF, et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell. 2009 Aug 28;35(4):534–541.
   PubMed Web of Science ®Google Scholar
• Iwabuchi K, Bartel PL, Li B, et al. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6098–6102.
   PubMed Web of Science ®Google Scholar
• Wang B, Matsuoka S, Carpenter PB, et al. 53BP1, a mediator of the DNA damage checkpoint. Science. 2002 Nov 15;298(5597):1435–1438.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010 Jun;17(6):688–695.
   PubMed Web of Science ®Google Scholar
• Bunting SF, Callen E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010 Apr 16;141(2):243–254.
   PubMed Web of Science ®Google Scholar
• Kass EM, Moynahan ME, Jasin M. Loss of 53BP1 is a gain for BRCA1 mutant cells. Cancer Cell. 2010 May 18;17(5):423–425.
   PubMed Web of Science ®Google Scholar
• Chapman JR, Barral P, Vannier JB, et al. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol Cell. 2013 Mar 7;49(5):858–871.
   PubMed Web of Science ®Google Scholar
• Gottipati P, Vischioni B, Schultz N, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010 Jul 1;70(13):5389–5398.
   PubMed Web of Science ®Google Scholar
• Liu X, Han EK, Anderson M, et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res. 2009 Oct;7(10):1686–1692.
   PubMed Web of Science ®Google Scholar
• Zaremba T, Ketzer P, Cole M, et al. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer. 2009 Jul 21;101(2):256–262.
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006 Aug 15;66(16):8109–8115.
   PubMed Web of Science ®Google Scholar
• Moghadasi S, Hofland N, Wouts JN, et al. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling. J Med Genet. 2013 Feb;50(2):74–79.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Van Der Gulden H, Van Der Heijden I, et al. A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov. 2013 Oct;3(10):1142–1155.
   PubMed Web of Science ®Google Scholar
• Eccles DM, Mitchell G, Monteiro AN, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol. 2015 Oct;26(10):2057–2065.
   PubMed Web of Science ®Google Scholar
• Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011 Aug 1;29(22):3008–3015.
   PubMed Web of Science ®Google Scholar
• Joosse SA, van Beers EH, Tielen IH, et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat. 2009 Aug;116(3):479–489.
   PubMed Web of Science ®Google Scholar
• Vollebergh MA, Lips EH, Nederlof PM, et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol. 2011 Jul;22(7):1561–1570.
   PubMed Web of Science ®Google Scholar
• Davies H, Glodzik D, Morganella S, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017 Apr;23(4):517–525.
   PubMed Web of Science ®Google Scholar
• Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016 Apr;2(4):482–490.
   PubMed Web of Science ®Google Scholar
• Watkins JA, Irshad S, Grigoriadis A, et al. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014 Jun 3;16(3):211.
   PubMed Web of Science ®Google Scholar
• Timms KM, Abkevich V, Hughes E, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014 Dec 5;16(6):475,014-0475-x.
   PubMed Web of Science ®Google Scholar
• Patel J, Sehouli J, Timms K, et al. Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC). Ann Oncol. 2016;27(suppl_6):113
   Google Scholar
• Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016 Aug 1;22(15):3764–3773.
   PubMed Web of Science ®Google Scholar
• Haaf T, Golub EI, Reddy G, et al. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2298–2302.
   PubMed Web of Science ®Google Scholar
• Yuan SS, Lee SY, Chen G, et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 1999 Aug 1;59(15):3547–3551.
   PubMed Web of Science ®Google Scholar
• Shah MM, Dobbin ZC, Nowsheen S, et al. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol. 2014 Aug;134(2):331–337.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010 Apr 15;16(8):2344–2351.
   PubMed Web of Science ®Google Scholar
• van Veelen LR, Essers J, van de Rakt MW, et al. Ionizing radiation-induced foci formation of mammalian Rad51 and Rad54 depends on the Rad51 paralogs, but not on Rad52. Mutat Res. 2005 Jul 1;574(1–2):34–49.
   PubMed Web of Science ®Google Scholar
• Wohlschlegel JA, Kutok JL, Weng AP, et al. Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am J Pathol. 2002 Jul;161(1):267–273.
   PubMed Web of Science ®Google Scholar
• Naipal KA, Verkaik NS, Ameziane N, et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res. 2014 Sep 15;20(18):4816–4826.
   PubMed Web of Science ®Google Scholar
• Mutter RW, Riaz N, Ng CK, et al. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J Pathol. 2017 Mar 15. doi:10.1002/path.4890.
   PubMedGoogle Scholar
• Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010 Dec 15;16(24):6159–6168.
   PubMed Web of Science ®Google Scholar